Cite
HARVARD Citation
Müller, R. et al. (2022). An update on the use of tolvaptan for autosomal dominant polycystic kidney disease: consensus statement on behalf of the ERA Working Group on Inherited Kidney Disorders, the European Rare Kidney Disease Reference Network and Polycystic Kidney Disease International. Nephrology dialysis transplantation. 37 (5), pp. 825-839. [Online].